Phong Nguyen Thanh, Duc Hong Du, Ho Bich Hai, Nguyen Thanh Nguyen, Le Dinh Van Khoa, Le Thuy Thuy Khanh, Luu Hoai Bao Tran, Nguyen Thi My Linh, Cao Thi Cam Van, Dang Phuong Thao, Nguyen Thi Diem Trinh, Pham Tieu Kieu, Nguyen Thanh Truong, Vo Tan Hoang, Nguyen Thanh Ngoc, Tran Thi Dong Vien, Vo Trieu Ly, Tran Dang Khoa, Abi Beane, James T Anibal, Guy Thwaites, Ronald B Geskus, David Clifton, Nguyen Thi Phuong Dung, Evelyne Kestelyn, Guy Glover, Le Van Tan, Lam Minh Yen, Nguyen Le Nhu Tung, Nguyen Thanh Dung, C. Louise Thwaites
{"title":"清醒俯卧位对中重度 COVID-19 的有效性随机对照试验。","authors":"Phong Nguyen Thanh, Duc Hong Du, Ho Bich Hai, Nguyen Thanh Nguyen, Le Dinh Van Khoa, Le Thuy Thuy Khanh, Luu Hoai Bao Tran, Nguyen Thi My Linh, Cao Thi Cam Van, Dang Phuong Thao, Nguyen Thi Diem Trinh, Pham Tieu Kieu, Nguyen Thanh Truong, Vo Tan Hoang, Nguyen Thanh Ngoc, Tran Thi Dong Vien, Vo Trieu Ly, Tran Dang Khoa, Abi Beane, James T Anibal, Guy Thwaites, Ronald B Geskus, David Clifton, Nguyen Thi Phuong Dung, Evelyne Kestelyn, Guy Glover, Le Van Tan, Lam Minh Yen, Nguyen Le Nhu Tung, Nguyen Thanh Dung, C. Louise Thwaites","doi":"10.1101/2024.06.30.24309722","DOIUrl":null,"url":null,"abstract":"Objectives: We evaluated the efficacy and acceptability of awake-prone positioning (APP) in a randomised controlled trial, using a dedicated APP implementation team and wearable continuous-monitoring devices to monitor position and oximetry.\nMethods: The trial was performed at a tertiary level hospital in Ho Chi Minh City, Vietnam, recruiting adults (≥18 years) hospitalised with moderate or severe COVID-19 and receiving supplemental oxygen therapy via nasal/facemask systems or high-flow nasal canulae. Participants were randomized (1:1) to standard care or APP. The primary outcome was escalation of respiratory support within 28 days of randomisation.\nResults: Ninety-three patients were enrolled between March 2022 and March 2023; 80 (86%) had received ≥2 doses of SARS-CoV2 vaccine. Significantly greater mean daily APP times were achieved in those allocated to APP, although most did not achieve the target 8 hours/day. We did not detect significant differences in the primary outcome (RR 0.85, 95% CI 0.40-1.78, p=0.67) or secondary outcomes, including intubation rate and 28-day mortality. Particpants reported prone positioning was comfortable, although almost all preferred supine positioning. No adverse events associated with the intervention were reported.\nConclusions: APP was not associated with benefit, but was safe. Continuous monitoring with wearable devices was feasible and acceptable to patients.","PeriodicalId":501249,"journal":{"name":"medRxiv - Intensive Care and Critical Care Medicine","volume":"19 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Awake prone positioning effectiveness in moderate to severe COVID-19 a randomized controlled trial.\",\"authors\":\"Phong Nguyen Thanh, Duc Hong Du, Ho Bich Hai, Nguyen Thanh Nguyen, Le Dinh Van Khoa, Le Thuy Thuy Khanh, Luu Hoai Bao Tran, Nguyen Thi My Linh, Cao Thi Cam Van, Dang Phuong Thao, Nguyen Thi Diem Trinh, Pham Tieu Kieu, Nguyen Thanh Truong, Vo Tan Hoang, Nguyen Thanh Ngoc, Tran Thi Dong Vien, Vo Trieu Ly, Tran Dang Khoa, Abi Beane, James T Anibal, Guy Thwaites, Ronald B Geskus, David Clifton, Nguyen Thi Phuong Dung, Evelyne Kestelyn, Guy Glover, Le Van Tan, Lam Minh Yen, Nguyen Le Nhu Tung, Nguyen Thanh Dung, C. Louise Thwaites\",\"doi\":\"10.1101/2024.06.30.24309722\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: We evaluated the efficacy and acceptability of awake-prone positioning (APP) in a randomised controlled trial, using a dedicated APP implementation team and wearable continuous-monitoring devices to monitor position and oximetry.\\nMethods: The trial was performed at a tertiary level hospital in Ho Chi Minh City, Vietnam, recruiting adults (≥18 years) hospitalised with moderate or severe COVID-19 and receiving supplemental oxygen therapy via nasal/facemask systems or high-flow nasal canulae. Participants were randomized (1:1) to standard care or APP. The primary outcome was escalation of respiratory support within 28 days of randomisation.\\nResults: Ninety-three patients were enrolled between March 2022 and March 2023; 80 (86%) had received ≥2 doses of SARS-CoV2 vaccine. Significantly greater mean daily APP times were achieved in those allocated to APP, although most did not achieve the target 8 hours/day. We did not detect significant differences in the primary outcome (RR 0.85, 95% CI 0.40-1.78, p=0.67) or secondary outcomes, including intubation rate and 28-day mortality. Particpants reported prone positioning was comfortable, although almost all preferred supine positioning. No adverse events associated with the intervention were reported.\\nConclusions: APP was not associated with benefit, but was safe. Continuous monitoring with wearable devices was feasible and acceptable to patients.\",\"PeriodicalId\":501249,\"journal\":{\"name\":\"medRxiv - Intensive Care and Critical Care Medicine\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Intensive Care and Critical Care Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.06.30.24309722\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Intensive Care and Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.06.30.24309722","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Awake prone positioning effectiveness in moderate to severe COVID-19 a randomized controlled trial.
Objectives: We evaluated the efficacy and acceptability of awake-prone positioning (APP) in a randomised controlled trial, using a dedicated APP implementation team and wearable continuous-monitoring devices to monitor position and oximetry.
Methods: The trial was performed at a tertiary level hospital in Ho Chi Minh City, Vietnam, recruiting adults (≥18 years) hospitalised with moderate or severe COVID-19 and receiving supplemental oxygen therapy via nasal/facemask systems or high-flow nasal canulae. Participants were randomized (1:1) to standard care or APP. The primary outcome was escalation of respiratory support within 28 days of randomisation.
Results: Ninety-three patients were enrolled between March 2022 and March 2023; 80 (86%) had received ≥2 doses of SARS-CoV2 vaccine. Significantly greater mean daily APP times were achieved in those allocated to APP, although most did not achieve the target 8 hours/day. We did not detect significant differences in the primary outcome (RR 0.85, 95% CI 0.40-1.78, p=0.67) or secondary outcomes, including intubation rate and 28-day mortality. Particpants reported prone positioning was comfortable, although almost all preferred supine positioning. No adverse events associated with the intervention were reported.
Conclusions: APP was not associated with benefit, but was safe. Continuous monitoring with wearable devices was feasible and acceptable to patients.